BTK and glioblastoma: Ibrutinib, a prototype BTK inhibitor and US Food and Drug Administration-approved drug for hematological malignancy, has shown remarkable efficacy in reducing the proliferation, stemness, and invasion of GBM cells in vitro and in vivo, leading to over 400 registered clinical trials [9,43,46,55].